ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mié, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Crecimiento histórico y gran apuesta por la Investigación
ROVI incrementa un 54% los ingresos operativos y un 151% el...
8 min
14/06/2022
Al cierre del primer trimestre de 2022
ROVI AUMENTA UN 123% SU BENEFICIO NETO Y ALCANZA LOS 53,0 MILLONES DE EUROS
La farmacéutica...
8 min
11/05/2022
Madrid – 08 Abril, 2022 - Moderna y ROVI Pharmaceutical Services, S. A. U. han anunciado hoy la retirada de un lote (nº 000190A) de la...
2 min
08/04/2022
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.